RE:RE:RE:RE:RE:I don't see a mystery Eoganacht ... Nice observation. IRBX N-803 has no future as a stand-alone. It needs to be combined with BCG, whose supply shortage will remain for years, as per Merck itself.
_______________
Eoganacht - (4/18/2023 3:32:03 PM)
RE:RE:RE:RE:I don't see a mystery
Plus this is a combo treatment which is dependent on BCG which is in short supply and will remain so for years to come. The new Merck facility to increase BCG production won't be ready before late 2025 at the earliest.
N-803 plus BCG has good efficacy but N-803 as a standalone treatment doesn't do so well. Cohort C in the recent Quilt-3.032 trial was comprised of NMIBC patients who received only N-803. It was discontinued because of poor results.